Cardio Diagnostics Holdings (CDIO) Times Interest Earned (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Times Interest Earned of -$27.2 for Q1 2026, up 95.74% sequentially from -$638.4 in Q4 2025, and down 8.16% YoY from -$29.62 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Times Interest Earned (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Times Interest Earned for 6 years, with the latest figure at -$27.2 in Q1 2026.
- Quarterly Times Interest Earned fell 8.16% year-over-year to -$27.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$48.86 (down 5527.94% YoY) and the FY2025 annual result came in at -$24.88, down 1567.69% from the prior year.
- Times Interest Earned advanced to -$27.2 in Q1 2026 per CDIO's latest filing, from -$638.4 in the prior quarter.
- Over five years, Times Interest Earned peaked at $0.23 in Q4 2023 and troughed at -$638.4 in Q4 2025.
- A 5-year average of -$119.69 and a median of -$9.84 in 2025 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2023 and 2024: Times Interest Earned surged 100.06% in 2023, then tumbled 208213.64% in 2024.
- Over 5 years, Times Interest Earned stood at -$407.97 in 2022, then soared by 100.06% to $0.23 in 2023, then sank by 208213.64% to -$484.94 in 2024, then plunged by 31.65% to -$638.4 in 2025, then soared by 95.74% to -$27.2 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$27.2, -$638.4, and -$16.77 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 2.82 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.08 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.42 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 76.86 |
| 10 | Cardio Diagnostics Holdings | 6.42 Mn | 835,350.96 | - | -435.51 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.76 |
| Mar 31, 2026 | -27.20 |
| Dec 31, 2025 | -638.40 |
| Sep 30, 2025 | -16.77 |
| Jun 30, 2025 | -2.91 |
| Mar 31, 2025 | -25.15 |
| Dec 31, 2024 | -484.94 |
| Sep 30, 2024 | -1.83 |
| Jun 30, 2024 | -1.53 |
| Mar 31, 2024 | -64.91 |
| Dec 31, 2023 | 0.23 |
| Sep 30, 2023 | -1.47 |
| Jun 30, 2023 | -2.43 |
| Mar 31, 2023 | -0.34 |
| Dec 31, 2022 | -407.97 |
| Dec 31, 2021 | -0.42 |